PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.

Guowei KimHon Lyn TanRaghav SundarBettina LieskeCheng Ean CheeJingshan HoAsim ShabbirMaria V BabakWee Han AngBoon Cher GohWei Peng Yong Ling-Zhi WangJimmy B Y So

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The recommended phase II dose is 120 mg/m2. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases.See related commentary by de Jong et al., p. 1830.

Keyphrases

phase ii
clinical trial
open label
current status
phase iii
randomized controlled trial
case control
radiation therapy
squamous cell carcinoma